93 results about "Basal bolus" patented technology

The invention discloses a self-crosslinking hydrogel with a tertiary amine group and preparation and application thereof, and belongs to the field of biomedical polymer materials, the self-crosslinking hydrogel comprises aminophenylboronic acid modified oxidized glucan, tertiary amine compound modified oxidized glucan and a solvent medium; the preparation method comprises the following steps: dissolving amino phenylboronic acid modified oxidized dextran and tertiary amine compound modified oxidized dextran in a solvent medium, mixing, standing for a certain time, and carrying out self-crosslinking to obtain the self-crosslinking hydrogel with tertiary amine groups. A cross-linking point (phenylboronic acid) of the gel network is a response unit of glucose. In addition, the hydrogel can effectively avoid uncontrollable drug release caused by non-responsive factors, and the response release efficiency of the drug is improved; by loading the hypoglycemic drug insulin to be applied to the treatment research process of diabetes, the occurrence of hypoglycemia can be avoided, and meanwhile, the possibility is provided for realizing intelligent controlled release of insulin through blood glucose response.

The invention discloses a carbon-based catalyst and a preparation method and application thereof to isomerization of glucose into fructose, the catalyst comprises an active component loaded on a carbon-based catalyst carrier and a chelating agent complexed with the active component, metal salts in the active component are Mg and K, the chelating agent is one or more of citric acid, triacetic acid, triethylamine ethylenediamine and potassium sodium tartrate. The chelating agent adjusts alkali active sites of a reaction system through acidic functional groups of the chelating agent, maintains an acid-base environment required by the reaction, and promotes an isomerization reaction from glucose to fructose. Meanwhile, the chelating agent and the metal ions form a stable complex to prevent metal salt from inactivation, and the metal ions are ensured to be uniformly distributed on the surface of the carrier and prevented from being agglomerated through the dispersity of the chelating agent, so that the activity and stability of the catalyst are improved. By controlling the dosage of the chelating agent and coordination of metal ions, the selectivity of the glucose isomerization reaction and the fructose yield are effectively improved, side reactions are inhibited, and the overall efficiency of the reaction is remarkably improved.

The invention discloses a hypoglycemic composition containing supramolecular group composite peptide. The hypoglycemic composition comprises collagen peptide, soybean peptide, bitter gourd peptide, bamboo leaf flavone, L-carnitine and the like. The composition prepared by selecting raw material components of specific types and dosages has the effects of remarkably reducing the glucose level and increasing the insulin level, and part of the composition can also cooperate with metformin to achieve the effects of enhancing the effect of reducing blood sugar and improving or preventing type 2 diabetes mellitus. Therefore, the method can be used for developing functional foods and medicines and has a considerable market prospect.

The invention is applicable to the technical field of material preparation and electrochemical sensing, and discloses a graphdiyne oxide gold nanoparticle composite electrode, a preparation method and application of the graphdiyne oxide gold nanoparticle composite electrode in a non-enzymatic glucose electrochemical sensor. Preparing the prepared graphdiyne oxide into an aqueous dispersion, taking carbon cloth as a substrate electrode, soaking the carbon cloth in the graphdiyne oxide dispersion after ethanol soaking, drying and surface treatment, drying, then soaking the carbon cloth in the prepared gold nanoparticle solution, and heating and drying to obtain the graphdiyne oxide gold nanoparticle composite electrode; the graphdiyne oxide and the gold nanoparticles are uniformly distributed on the surface of the carbon cloth. Due to the fact that rich oxygen-containing groups on the graphdiyne oxide can cooperate with the gold nanoparticles to promote catalytic oxidation of glucose, the non-enzymatic glucose electrochemical sensor prepared based on the electrode material has high catalytic activity on glucose and shows high sensitivity, selectivity and stability.

The application discloses a benzothiophenone derivative, a preparation method and application thereof. The benzothiophenone derivative, a tautomer, an optical isomer, a hydrate, a solvate, a pharmaceutically acceptable salt or a prodrug thereof, and the chemical structure of the benzothiophenone derivative is shown as formula (I), wherein R is any one of the following groups: a substituted alkane and N-benzyl-2-chloroformamide. The benzothiophenone derivative can regulate a PPARγ target as an anti-type 2 diabetes drug, can reserve insulin sensitivity, can avoid related side effects caused by a PPARγ full agonist, and has a 'highly efficient and safe' hypoglycemic effect.

The present disclosure relates to poly alpha-1,6-glucan ether compounds comprising poly alpha-1,6-glucan substituted with at least one positively charged organic group and having a degree of substitution of about 0.001 to about 3.0. The poly alpha-1,6-glucan comprises a backbone of glucose monomer units, wherein greater than or equal to 40% of the glucose monomer units are linked via alpha-1,6 glycosidic bonds, and optionally about 3% of the backbone glucose monomer units have branches via alpha-1,2 and / or alpha-1,3 glycosidic bonds. Compositions comprising poly alpha-1,6-glucan ether compounds can be used in various applications.

The invention provides a glucose hydrogel optical fiber sensor and a preparation method thereof. The glucose hydrogel optical fiber sensor comprises an optical fiber and a glucose fluorescence sensing module fixedly carried on the end face of the optical fiber. Wherein the optical fiber comprises a double-layer hydrogel optical fiber which comprises an inner fiber core and an outer cladding. The glucose fluorescence sensing module is formed by fixing a glucose fluorescence probe containing a boric acid group and a terminal amino group through a covalent reaction between the amino group and an epoxy group in the hydrogel network. The glucose hydrogel optical fiber sensor has excellent performance, high sensitivity and good selectivity, and can realize stable and real-time detection of glucose concentration in a complex physiological environment. The sensor is flexible in structure and good in biocompatibility, does not depend on enzyme reaction, and avoids the problem of signal drift caused by enzyme inactivation; meanwhile, the sensor is good in repeatability, can be integrated with other optical sensing modules to realize multi-parameter synchronous monitoring, and is suitable for long-term dynamic monitoring application in vivo.

The invention discloses a sulfonated MXene sensing layer, a preparation method thereof and a biosensor, and belongs to the technical field of electrochemical sensors. The sensing layer contains a sulfonated MXene material, and the sulfonated MXene material is obtained by performing covalent bond modification on a sulfonic acid group on the MXene material. According to the preparation method, sulfonic acid groups are covalently grafted on the surface of MXene through plasma treatment, so that the MXene has high specific surface area, excellent electron conductivity, efficient enzyme immobilization capability and H2O2 catalytic decomposition activity. The biosensor constructed based on the sensing layer comprises a flexible substrate, a three-electrode system and a limited diffusion layer, the response speed, the detection precision, the stability and the anti-interference performance (such as uric acid resistance and ascorbic acid resistance) of the sensor are remarkably improved, and the biosensor is particularly suitable for being applied to an implantable continuous glucose monitoring system.

The invention relates to a lipid molecule, and a composition and application thereof. The core structure of the lipid-like molecule covers a two-dimensional plane structure and a plurality of three-dimensional structures, and endows the LNP with adjustable membrane tissue characteristics and intracellular transport behaviors, so that a new strategy of adjusting delivery performance from the structural level is realized. In addition, part of the ionizable lipid is introduced into a fluorine substituent group, so that the internal hydrophobic interaction and colloidal stability of the LNP are improved, and the in-vivo delivery persistence is prolonged. The invention also provides a component-simplified LNP delivery system based on programmable regulation and control of ionizable lipid chemical bonds, which is different from the traditional strategy of needing to remove hepatic tropism components (such as cholesterol) or additionally introduce targeted regulation and control lipid (a fifth component) to realize organ targeting. Selective delivery of organs such as liver, spleen, lung, pancreas and the like can be realized under the condition of retaining cholesterol only by changing the type of a chemical bond between an aliphatic chain and a core structure in the ionizable lipid.

The disclosure concerns a use of a compound for the preparation of an additive, a premix or a food or fodder, for animal feeding, said compound corresponding to the following formula:in whichR1 is selected from C1-11 alkyl groups;R2 is selected from C1-20 alkyl groups; CmH2m—OR4; CmH2m—NHR4 where R4 is selected from H and C(O)—C1-11 alkyl and m is equal to 0 or represents an integer from 1 to 11;R3 is selected from H and C1-20 alkyl groups;n is 0 or an integer from 1 to 10; andk is an integer from 1 to 10;or a salt of said compound.

The present invention belongs to the technical field of insulin derivatives. Disclosed are a phenylboronic-acid-based insulin derivative, and a preparation method therefor and the use thereof. The provided phenylboronic-acid-based insulin derivative has a good glucose-responsive release function, wherein the phenylboronic acid group binds to a glycosyl protein to generate a phenylboronic acid ester bond, thereby generating an insulin and glycosyl protein complex in situ in blood. When the concentration of glucose in the blood is high, the glucose specifically cleaves the phenylboronic acid ester bond, thereby releasing the insulin. The provided phenylboronic-acid-based insulin derivative achieves stable and rapid glucose-responsive insulin release, which can steadily and persistently maintain the blood glucose of a diabetic subject within the normal range with almost no occurrence of hypoglycemia.

The invention relates to the technical field of food-grade materials, in particular to a food-grade porous material and a preparation method thereof. The preparation method comprises the following steps: gradually carrying out enzymolysis on corn flour by alkaline protease and amylase under the conditions of proper temperature and pH, continuously stirring, adding food-grade vegetable gum, and forming porous glycoprotein under the assistance of ultrasonic waves; the porous glycoprotein is uniform in pore size and is 0.5-3 microns, and the surface of the porous glycoprotein is rich in functional groups, so that the porous glycoprotein has good adsorption performance and has very high adsorbability on hydrophobic compounds such as metal ions, pesticide residues, kitchen oil stains and the like. The preparation process is simple, chemical reagents do not need to be introduced, and safe and non-toxic substances are completely adopted as materials for preparing the porous material, so that the product is food-grade, small in damage to human bodies and the environment and wide in application in the food field.

The invention relates to physically stable compositions in the form of an injectable aqueous solution, having a pH between 6.0 and 8.0, comprising at least: a) a basal insulin having an isoelectric point (pI) between 5.8 and 8.5 and b) a co-polyamino acid bearing carboxylate charges and at least one hydrophobic radical.

The invention discloses a partial acylated non-natural sugar for metabolic labeling and application, the partial acylated non-natural sugar is a mannose type of a pyranose structure, and 1-hydroxyl and 6-hydroxyl are protected by hydrophobic groups. According to the method, the advantages of existing non-natural sugar are taken into consideration, it is guaranteed that the non-natural sugar can be efficiently utilized by cells, S side reaction of the non-natural sugar and cysteine in protein in the metabolism process is effectively avoided, and meanwhile efficient metabolism marking is achieved. In a cell test, the use concentration of the 1, 6-diacylated non-natural sugar is one order of magnitude lower than that of the non-natural sugar without the protecting group.

The invention belongs to the technical field of protein beverages, and particularly relates to a composite peptide beverage and a preparation process thereof. The active ingredients of the drink comprise calf thymosin, cattle spleen protein peptide, hemoglobin peptide, bone collagen peptide and collagen peptide in a weight ratio of (2-3): 1: 1: 1: 1. The pH value of the system is adjusted to 3.5-4.5, so that each peptide molecule is positively charged under the acidic condition, the electrostatic repulsion and hydration among molecules are enhanced, and bitter groups are effectively masked. The flavoring agent is compounded by DL-malic acid, crystalline fructose, xylitol and sucralose according to the weight ratio of (0.6-1): 1: 0.4: (0.03-0.04), and the sour and sweet taste and flavor coordination are synergistically improved. The preparation method comprises the following steps: dissolving the DL-malic acid in purified water, dissolving the uniformly mixed active components in purified water at 40-60 DEG C, respectively adding other flavoring agents, stabilizing agents and essence, and finally filtering to obtain the product. The problem of bad flavor of the peptide is solved, so that the beverage is appropriate in taste, harmonious in flavor and easy to accept.

The invention discloses a pyrrole biphenyl derivative compound as well as a preparation method and application thereof in pharmacy, and belongs to the technical field of chemical medicine raw material medicine and preparation manufacturing. The compound has a structure as shown in # imgabs0 #. The compound is specifically combined with SGLT-2 protein through a pyrrole-benzene conjugated system, the glucose transport function of the SGLT-2 protein is inhibited, and the IC50 value of the SGLT-2 protein reaches 15-105 nM. The traditional Chinese medicine composition is suitable for preparing medicines for treating non-alcoholic liver diseases, solid tumors, hematological malignant tumors and autoimmune diseases, and especially has a remarkable effect on abnormal glycolipid metabolism of liver cells and energy deprivation of tumor cells. The compound has deuterated group enhanced metabolic stability, and can be prepared into dosage forms such as tablets, capsules, injection and the like.

The present disclosure provides a compound of formula (I): or a pharmaceutically acceptable salt thereof, wherein: X1 is CH or N; p is 0, 1 or 2; wherein: each R1 is a substituent on any C atom and is independently selected from the group consisting of F, Cl, C1-3 alkyl and C1-3 alkoxy wherein the C1-3 alkyl and C1-3 alkoxy may be independently optionally substituted by one or more F; rN is selected from H and Me; n is 0, 1 or 2; m is 0 or 1; q1 is CH or N; q2 is CH or N when neither n nor m is 0; when both n and m are 0, Q2 is CH; when n is 0 or 1, Q3 is CH; when n is 2 and Q2 is N, Q3 is CH; when n is 2 and Q2 is CH, Q3 is CH or O; r2a and R2b are substituents on the same or different C atoms other than at Q1 or Q2, each independently selected from H, F and C1-3 alkyl, or R2a and R2b together form a-(CH2) r-group wherein r is 1, 2 or 3; q4 is a single bond or-NR4C (= O); r4 is H or Me; 0, 1, or 2 of Y1, Y2, Y3, Y4, and Y5 is N, otherwise C; each R3 is a substituent on any C atom at Y1, Y2, Y3, Y4 and Y5 and is independently selected from the group consisting of F, Cl, CN, C1-3 alkyl and C1-3 alkoxy wherein the C1-3 alkyl and C1-3 alkoxy may be independently optionally substituted by one or more F; q is 0, 1 or 2; wherein the linker is attached to any available C atom at Y4 and Y5; the linker is a saturated or partially or fully unsaturated framework comprising a C atom and an H atom and at least one heteroatom, wherein the framework has a length of 5 to 26 atoms connecting the endpoints'a 'and'b' and between'a 'and'b'; wherein the framework may comprise one or more linear and / or branched chains and / or rings and are optionally substituted by one or more F on any available C atom; and W is an E3 ubiquitin ligase cerebron binding agent unit.

[Problem] The purpose of the present invention is to provide a polymerizable boronic acid compound that has a structure different from both an azobenzene moiety and an acrylamide phenylboronic acid structure and makes it possible to detect a change in glucose concentration by forming glucose and a cyclic boronic acid ester. [Solution] The problem is solved by a polymerizable boronic acid compound or the like represented by general formula (1) (in the formula, at least one of R1 to R7 denotes a substituent having a polymerizable group, and the remaining moieties independently denote a substituent selected from the group consisting of a hydrogen atom, a hydroxy group, a carboxyl group, an amino group, and an alkyl group).

A compound comprising a peptide chain which is an analogue of amylin, a terminal —NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The present invention relates to saccharide sensing systems including macrocyclic compounds which are capable of binding to a target saccharide (e.g. glucose) and a detectable reporter for providing a detectable signal based on the binding of the target saccharide by the macrocyclic compound.

Provided are: an anti-obesity agent, an anti-inflammatory agent, a brain function improving agent, a liver function improving agent, a bone strengthening agent, a blood sugar level improving agent, and a muscle enhancing agent each containing a compound represented by general formula (1) as an active ingredient; and an oral composition and a cosmetic composition each containing at least any one of the above-mentioned agents. (In general formula (1), R1 represents H or a group represented by general formula (2). In general formula (2), * represents a bond.)

A compound of formula (I) or a pharmaceutically acceptable salt thereof, wherein X 1 is CH or N, p is 0, 1, or 2, where each R 1 is a substituent on any C atom and is independently selected from F, Cl, C 1~3 alkyl, and C 1~3 alkoxy, and the C 1~3 alkyl and C 1~3 alkoxy may each be optionally substituted by one or more Fs, R N is selected from H and Me, n is 0, 1, or 2, m is 0 or 1, Q 1 is CH or N, and when both n and m are other than 0, Q 2 is CH or N, and when both n and m are 0, Q 2 is CH, and when n is 0 or 1, Q 3 is CH, and when n is 2 and Q 2 is N, Q 3 is CH, and when n is 2 and Q 2 is CH, Q 3 is CH or O, and R 2a and R 2b are substituents on the same or different C atoms other than Q 1 or Q 2 and are each independently selected from H, F, and C 1~3 alkyl, or R 2a and R 2b together form a -(CH2) r - group, where r is 1, 2, or 3, Q 4 is a single bond or -NR 4 C(=O), R 4 is H or Me, Y 1 , Y 2 , Y 3 , Y 4 , and Y 5 of which 0, 1, or 2 are N and otherwise C, and each R 3 is Y1, Y 2 , Y 3 , Y 4 , and Y 5A substituent on any C atom, independently of F, Cl, CN, C 1~3 Alkyl and C 1~3 Selected from alkoxy, the C 1~3 Alkyl and C 1~3 The alkoxy can be independently and optionally substituted by one or more Fs, where q is 0, 1, or 2, and the linker is Y. 4 and Y 5 A compound of formula (I) or a pharmaceutically acceptable salt thereof, bonded at any available C atom, the linker being a saturated, partially or fully unsaturated skeleton comprising C and H atoms and at least one heteroatom, the skeleton having bond endpoints "a" and "b" and having a length of 5 to 26 atoms between "a" and "b", the skeleton may contain one or more linear and / or branched and / or ring chains, optionally substituted on any available C atom with one or more F, and W being an E3 ubiquitin ligase cereblon binding unit. [Formula 1] JPEG2026510359000635.jpg38128

[Problem] To provide a dental caries suppression composition that is, in comparison with conventional anti-dental caries agents, capable of providing an even higher level of suppression of caries. [Solution] This composition contains: (A) an oligosaccharide that has a cyclic structure comprising glucose and / or a glucose derivative as a structural unit; and (B) a sugar other than the component (A). The component (A) is a cyclodextran and / or a cyclodextran derivative. The cyclodextran derivative has at least one of the alcoholic hydroxyl groups of cyclodextran substituted with another polar group. According to the present invention, the composition contains: (A) an oligosaccharide that has a prescribed cyclic structure comprising glucose and / or a glucose derivative as a structural unit; and (B) a sugar other than the component (A). The components (A) and (B) interact with one another in such a manner as to suppress dental caries. Consequently, suppression of dental caries at a higher level than that achieved by conventional anti-dental caries agents is realized.

A compound comprising a peptide chain which is an analogue of amylin, a terminal - NH2 group bound to the C terminal of the peptide chain, and an alkylene or alkenylene chain attached at the other end of the peptide chain or a derivative of the compound; or a salt or solvate of the compound or of the derivative. Compounds, derivates and salts, and related compositions are suitable for the prevention or treatment of diabetes, obesity, heart disease, stroke and non-alcoholic fatty liver disease, improving insulin release in a subject, improving carbohydrate metabolism in a subject, improving the lipid profile of a subject, improving carbohydrate tolerance in a subject, reducing appetite, reducing food intake, and / or reducing calorie intake, and related purposes.

The invention discloses a linalool glycosylation derivative as well as preparation and application thereof. The structure of the linalool glycosylation derivative is shown as a formula (I), R1, R2, R3, R4 and R5 groups are independently selected from H or a linalool group, and the preparation method comprises the following steps: taking linalool and glucose as raw materials, and catalytically synthesizing the linalool glycosylation derivative by using beta-glucosidase under an acidic heating condition. According to the linalool glycosylation derivative, the water solubility, the antibacterial property, the stability and the fragrance durability of the linalool glycosylation derivative are greatly improved by introducing the glucosyl group into the linalool. The derivative is suitable for various daily chemical products with antibacterial properties, and has a better industrial application prospect.

This invention discloses a pyrrolobenzene derivative compound, its preparation method, and its pharmaceutical application, belonging to the field of chemical pharmaceutical raw materials and formulation manufacturing technology. The compound has the structure shown. This compound specifically binds to the SGLT-2 protein through a pyrrolobenzene conjugated system, inhibiting its glucose transport function and affecting the IC50 of SGLT-2. 50 Values ​​range from 15 to 105 nM. Suitable for preparing drugs to treat non-alcoholic liver disease, solid tumors, hematological malignancies, and autoimmune diseases, especially effective against abnormal glucose and lipid metabolism in hepatocytes and energy deprivation in tumor cells. The compound possesses enhanced metabolic stability due to its deuterated group and can be formulated into tablets, capsules, injections, and other dosage forms.

A drug delivery system for administering a GLP-1 agonist therapy includes a reservoir configured to contain a GLP-1 agonist, a pump in fluid communication with the reservoir and configured to deliver the GLP-1 agonist, a controller operatively coupled to the pump, and a user interface operatively coupled to the controller. The controller is programmed to deliver a basal dose of the GLP-1 agonist continuously over a 24-hour period and deliver at least one bolus dose of the GLP-1 agonist in addition to the basal dose. The system allows for independent adjustment of basal and bolus doses based on patient-specific parameters, enabling personalized GLP-1 agonist therapy administration.

The present application discloses a phenyl boronic acid compound, which contains a phenyl boronic acid group and a carbon-carbon double bond group, and the phenyl boronic acid group can be combined with glucose. The present application also discloses a polymer, which is obtained by free radical copolymerization of the above-mentioned phenyl boronic acid compound, a monomer containing A and an initiator in a solvent. The present application further discloses an insulin sustained-release preparation containing the above-mentioned polymer, which has different insulin release rates under different glucose concentrations, and can accelerate the release of insulin under a hyperglycemic environment to reduce blood glucose. The present application further discloses a preparation method of the above-mentioned insulin sustained-release preparation, which self-assembles the negatively charged insulin and the positively charged double-phenyl boronic acid modified polymer into the insulin sustained-release preparation through electrostatic interaction, and has the characteristics of high loading rate. The prepared insulin sustained-release preparation can release insulin, and the released insulin can bind to insulin receptors in the body to reduce blood glucose level.

The invention relates to the technical field of biological medicine, in particular to a compound and a preparation method thereof, a photo-thermal agent and application of the photo-thermal agent in obesity treatment. The compound has a structure as shown in a formula I in the specification, wherein R is selected from at least one of anthracene-containing groups, dibenzothiophene-containing groups or carbazole-containing groups, and X is selected from at least one of halogen atoms, PF6 <-> and BF4 <->. The compound provided by the invention has mitochondrial targeting property and good photothermal conversion capability, and can realize obesity treatment by promoting the browning process of white adipose tissues.

The invention discloses a kind of polysaccharide iron identification method, comprise the steps:1) decomplexation, polysaccharide iron test sample is dissolved in water, adds phosphate decomplexation, precipitates, and takes supernatant;2) hydrolysis, takes step 1) in supernatant, with acid adjustment pH to acidity, heating is hydrolyzed, after the completion of hydrolysis, cooling, with alkali adjustment pH to 4 6, filters, and obtains polysaccharide acid solution;3) polysaccharide end group detection in polysaccharide iron, is detected using Agilent high performance liquid chromatograph, using the mixed solution of the polysaccharide sodium of glucose, corresponding polysaccharide iron as reference substance, detection step 2) whether the relative retention time of the polysaccharide acid sodium in hydrolysis solution is consistent with that in reference substance, to determine the polysaccharide acid category of polysaccharide iron;4) molecular weight determination of polysaccharide in polysaccharide iron. Using high performance liquid chromatography to determine the molecular weight and the R group of polysaccharide in polysaccharide iron, the purpose of differentiating the specific kind structure of polysaccharide is finally reached.